Outpatient Clinics Market Will Likely to Expand at a Steady CAGR of 4.3% by 2027

futuremarketinsights_logo

Growing advancements in medical technology has led to development of treatment techniques and medications that do not require the patients to stay for long hours at the clinics or hospitals. However, imposition of strict regulations will continue to hinder the global market growth of outpatient disorders over the forecast period. Future Market Insights states that the global market of outpatient clinics is projected to reflect a CAGR of 4.3%, representing more than US$ 39,000 Mn by 2022-end.

Factors Fuelling Global Market Growth

Growth of the global outpatient clinics market is mainly bound to various macro-economic and micro-economic factors. Prevalence of chronic diseases such as asthma, diabetes, depression and congestive heart failures lead to complex and severe health problems. With the escalating cost of treatment process in various healthcare organizations, patients prefer visiting the outpatient clinics for accessing treatment. Growing concerns regarding the increasing prevalence of cardiovascular diseases such as elevated blood pressure levels, hypertension, coronary heart diseases and cerebrovascular diseases has further led to surge in demand for the outpatient clinics globally.

Demand for quick and effective treatment of cardiovascular diseases will continue to contribute towards the global market growth of outpatient disorders. According to a recently published report by CDC, nearly 610,000 people die of heart attack in the U.S. each year, which is 1 in every 4 deaths. As cardiovascular diseases continue to remain a leading cause of mortality globally, demand for effective and quick treatment process will continue to remain high. These factors are projected to impact the global market growth of outpatient clinics throughout the forecast period.

Collaborations among the private insurance companies and outpatient clinics will continue to remain a major trend in the global market. Through collaborations the private insurance companies offer payment and services in outpatient clinics. Imposition of regulations such as Health Care and Educational Reconciliation Act and Patient Care Affordable Act provides the U.S. citizens with the public health insurance coverage and offers access to private health insurance services. Moreover, increasing employee benefits such as Employees’ health insurance by the employers is projected to contribute towards the global market growth of outpatient clinics over the forecast period.

However, the global market of outpatient clinics will continue to witness inhibiting growth attributed to various factors. Imposition of strict regulations and limited number of doctors for the treatment of various diseases will remain a key factor inhibiting demand for services offered by outpatient clinics. As the patients are not monitored for a long period of time, risk of addiction to alcohol and drugs is projected to remain high. Moreover, lack of access to counselors in comparison to the residential and inpatient facility is further projected to impede the global market growth of outpatient clinics.

Sales to Remain High Through Cardiology Specialty Areas

Prevalence of chronic and cardiovascular disorders is projected to fuel demand for the multi-specialty centers globally. In terms of revenue, the multi-specialty center type segment is projected to witness significant growth, representing more than US$ 8,400 Mn by 2022-end. Moreover, the multi-specialty center type segment is projected to reflect the fastest growth in the global market of outpatient clinics throughout the forecast period.

On the basis of specialty type, the dermatology segment is projected to reflect a significant CAGR through 2022. However, the cardiology specialty areas segment is projected to represent a robust revenue growth, recording more than US$ 3,000 Mn over the forecast period.

Market Players

Major players in the global market of outpatient clinics are Kaiser Permanente Inc., M D Anderson Cancer Center, Mayo Clinic, Memorial Sloan Kettering, University of Maryland Medical Center, DaVita Inc., Cleveland Clinic, Fresenius Medical Care and Johns Hopkins Medicine.

About Us 

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

T (UK): +44(0)20-7692-8790

Sales: sales@futuremarketinsights.com

Smita Deshmukh is a veteran digital marketing professional, having worked for numerous online firms in his distinguished career. She believes in continuous learning, considering that the digital marketing sector’s rapidly evolving nature.

7 Key Projections on Expansion of Syringes Market through 2022

Going forward, a majority of medical procedures in the global healthcare industry will be performed through invasive techniques. The demand for syringes will continue to prevail in the years to come, urging syringe manufacturers remain optimistic. Pivotal importance of syringes as a product in the surgicals industries is expected to remain intact. Fact.MR projects that in 2017, more than US$ 11.3 Bn will be spend by patients, hospitals and other end-users for buying syringes.

In addition to this, rising demand for multifunctional syringes will also shape the dynamics of global syringes market in the future. By the end of 2022, the global market for syringes will have expanded at a robust CAGR of 7.8%, recording an estimated revenues of US$ 16.5 Bn. Following insights are excerpted from this report, which offers key projections on the growth of global syringes market during 2017-2022.

  1. Firstly, the report highlights that North America and the Asia-Pacific excluding Japan (APEJ) regions will be at the forefront of global syringes market expansion. The APEJ syringes market will witness highest growth, bringing in revenues over US$ 5.7 Bn by 2022-end.
  2. Active reforms in the healthcare infrastructure across the US and Canada are likely to remain profitable for syringes market. In 2017, more than US$ 2.5 Bn worth of syringes will be sold in North America, which will soar vigorously through the forecast period to reflect 8.5% CAGR.
  3. Japan, on the other hand, is expected to showcase a sluggish revenue growth for its syringes market, exhibiting a CAGR of 4.3%. The report also projects that Europe’s syringe sales will rise steadily, raking over US$ 4 Bn by the end of 2022.
  4. With increasing complexity in medical & surgical procedures, the demand for specialized syringes is expected to remain higher than that of general syringes. The report expects that a little less than 30% of the global syringes market value will be attained by the sales of specialized syringes. Nevertheless, this contribution will remain dominant compared to general syringes, the sales of which are likely to amass revenues over US$ 3.5 Bn by the end of forecast period.
  5. Over 80% of syringes sold in the global market over the forecast period will be disposable. With that said, the demand for reusable syringes will not be listless, as revenues from global sales of such syringes will reflect a steady growth at 6% CAGR.
  6. The report also highlights that over two-third volume of syringes expected to be sold in the world will be accounted by hospitals. While hospitals will be the largest end-users for syringes, the report also projects that 99.4% of the global syringes market revenues will be arising from sales of polymer syringes through 2022.

According to the report, the companies that are anticipated to remain active in the expansion of global syringes market through 2022 include Becton, Dickinson and Company, B. Braun Melsungen AG, Gerresheimer AG, Hindustan Syringes & Medical Devices Limited, Terumo Corporation, Nipro Corporation, Schott AG, Medtronic PLC, Smiths Group plc., and Codan Medizinische Geräte GmbH & Co Kg.

About Fact.MR       
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com

Yogesh is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO.

Tuberculosis Drugs Market to Reflect Impressive Growth Rate by 2025

Tuberculosis (TB) is an infectious disease, which is caused by Mycobacterium tuberculosis. These bacteria generally infect human lungs. However, it can infect other body parts/organs as well. Three major types of tuberculosis are found: latent, active, and drug-resistant tuberculosis. Symptoms are not identifiable in case of latent tuberculosis, due to presence of an inactive form of bacteria. In active tuberculosis, symptoms are clearly visible and they can spread from one person to another. Coughing for more than two weeks, chest pain, coughing up blood, chills, fatigue, unintentional weight loss, fever, and loss of appetite are some of the common symptoms of active tuberculosis. HIV/AIDS, severe kidney disease, cancer, diabetes, and malnutrition are some of the key risk factors generally found to be associated with tuberculosis.

Tuberculosis can be diagnosed with the help of tests including blood tests, imaging tests (such as chest X-ray or CT scan), and sputum tests. Tuberculosis can be treated with the first-line or second-line therapy. As per a report by World Health Organization (WHO), tuberculosis is one of the leading causes of deaths occurring worldwide. In 2015, approximately 9 million new cases of TB and 1.5 million deaths caused by TB occurred worldwide. Currently, WHO and certain government agencies are working toward reduction of tuberculosis burden globally, with the help of programs such as Stop TB. In December 2015, Multi-Drug Resistant Tuberculosis Program was also launched to check the tuberculosis prevalence across the globe.

Growing prevalence of multi-drug resistant tuberculosis is driving the tuberculosis drugs market. Drug shortages is a major restraint for the tuberculosis drugs market, especially in low- to medium-income countries of the world. Tuberculosis associated with diseases such as HIV/AIDS and conditions such as obesity is extremely difficult to manage. The tuberculosis drugs market can be segmented based on drug class, disease type, end-user, and region. In terms of drug class, the market can be categorized into first-line therapy, second-line therapy, and combination therapy. Isoniazid, Pyrazinamide, Rifampin, and Ethambutol majorly constitute the first-line therapy for TB; while Streptomycin, Capreomycin, Ethionamide, Levofloxacin, and Gatifloxacin are generally considered as a part of the second-line therapy. Second-line therapy is expected to be a rapidly growing segment of the tuberculosis drugs market.

Based on disease type, the tuberculosis drugs market can be segmented into latent tuberculosis, active tuberculosis, and drug-resistant tuberculosis. The drug-resistant tuberculosis segment is expected to expand rapidly during the forecast period. In terms of distribution channel, the market can be divided into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held the leading share in the global tuberculosis drugs market in 2016. The segment is projected to expand at a significant CAGR during the forecast period. The others segment is expected to gain a significant market share during the forecast period, due to launch of national government programs.

In terms of geography, the global tuberculosis drugs market can be categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominated the global tuberculosis drugs market in 2016. Key factors responsible for growth of the market in Asia Pacific are presence of large patient population and high incidence rate of TB, especially in some of the developing economies of the region such as India and China. On the other hand, North America and Europe have a relatively small-sized patient pool with lower incidence rate of the disease. However, high awareness, well-developed health care infrastructure, rapid adoption of advanced yet expensive TB tests, and high purchasing power are driving the market in these regions.

Key players operating in the global tuberculosis drugs market are Sanofi, Novartis AG, Bayer AG, Lupin Limited, Zydus Cadila, Merck & Co., Inc., Pfizer Inc., and AstraZeneca.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Shreyas is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO

5 Key Takeaways from Fact.MR’s Report on Prostate Cancer Diagnostics Market

According to the latest report by Fact.MR, the global prostate cancer diagnostics market is anticipated to exhibit a steady expansion at 5.3% CAGR during the forecast period 2017 to 2022. In terms of revenues, the market is projected to reach US$ 823.5 Mn in 2017; by 2022 this number is projected to surpass US$ 1,000 Mn.

Diagnosis of prostate cancer is becoming a critical undertaking for medical organizations. Newer treatments on prostate cancer are being developed by considering the scope of diagnostic approach. This emergence of diagnosis-associated treatments on prostate cancer is expected to render higher medical efficiency, providing effective outputs at minimal healthcare spending. Through and through, medical organizations are scanning key criteria associated with diagnosis of prostate cancer, tracking parameters such as age of the patient, ethnicity, family medical history, and diet. Considering the sensitivity of organs in the prostate area, patients are also adopting non-invasive diagnosis tests, which is ultimately impacting the products sold in the global market for prostate cancer diagnostics.

Advancements in technology for finding newer techniques for treatment & diagnostics of prostate cancer, changing lifestyles of people across the globe, and the rise in funding from both private as well as public sector in the development of drugs are some factors influencing growth of the global market for prostate cancer diagnostics. Serum-based market testing is being widely adopted for prostate cancer diagnostics. In order to enhance the test’s sensitivity, it is being evaluated with several other cancer-specific markers. However, risks related to overtreatment and over-diagnosis of PSA screening is expected to incur challenges to growth of the global prostate cancer diagnostics market. However factors such as, high cost of treatment, surgical-associated risks such as blood clots, strokes, and heart attacks, and surgical side effects such as urinary incontinence & impotence are expected to curb growth of the market over the forecast period.

5 Estimations from Fact.MR’s Report on the Global Prostate Cancer Diagnostics Market

  1. North America will continue to be the most lucrative region in the global prostate cancer diagnostics market, in terms of revenues. The prostate cancer diagnostics market in North America and Europe are expected to exhibit similar CAGRs through 2022.
  2. The market in Asia-Pacific excluding Japan (APEJ) is expected to register the fastest expansion through 2022. In contrast, prostate cancer diagnostics market in Middle East & Africa will continue to register a sluggish expansion during the forecast period.
  3. PSA tests will continue to be the largest adopted tests for diagnosis of prostate cancer across the globe. PSA test segment is projected to register the highest CAGR in the market through 2022.
  4. Hospital-associated labs are expected to remain the largest end-users of prostate cancer diagnostics in the global market, however revenues from prostate cancer diagnostics in hospital-associated labs will register the lowest CAGR in the market through 2022.
  5. In terms of revenues, cancer research institutes are expected to register the highest CAGR in the market through 2022. Independent diagnostics labs will remain the second largest end users of the prostate cancer diagnostics during the forecast period.

The report has also profiled key players in the global market for prostate cancer diagnostics, which include Abbott Laboratories, AstraZeneca plc., Bayer Aktiengesellschaft, Danaher Corporation, Becton, Dickinson and Company, Foundation Medicine, Inc., Cancer Genetics, Inc., Myriad Genetics Inc., Agilent Technologies, and Biocept, Inc.

About Fact.MR       
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com

Yogesh is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO.

Global Spinal Cord Trauma Treatment Market Estimated to Exhibit of US$ 3,036.2 Mn by 2025

“Spinal Cord Trauma Treatment Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025” is the recent report of Persistence Market Research that throws light on the overall market scenario during the period of eight years, i.e. 2017-2025. According to this report, Global spinal cord trauma treatment market is expected to witness significant growth during the forecast period. This growth is expected to be primarily driven by increasing incidence of spinal cord trauma, and increasing government support to reduce the burden of spinal cord injuries. Additionally, development of nerve cells growth therapy is expected to boost the market in near future. The global market for spinal cord trauma treatment is is estimated to be valued at US$ 2,276.3 Mn in terms of value by the end of 2017. The global spinal cord trauma treatment market is expected to expand at a CAGR of 3.7% over the forecast period to reach a value of US$ 3,036.2 Mn by 2027 end.

Global Spinal Cord Trauma Treatment Market: Trends

  • Medical tourism for post spinal surgery rehabilitation
  • Research on neuroregeneration therapies
  • Increasing use of mechanical spinal traction
  • Focus towards improvement of quality of life by increasing the use of robot assisted rehabilitation
  • Methylprednisolone as a standard corticosteroid therapy
  • Public private partnership for better health infrastructure and work as a source to meet the funding gap
  • Increasing cases of vehicle accidents
  • Development of stem cell therapy

On the basis of end user, the global spinal cord trauma treatment market is segmented into hospitals and trauma centers. Hospitals segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Hospitals and trauma centers segments are expected to approximately similar attractive index. Hospitals segment accounted for 53.2% value share in 2017 and is projected to account for 52.5% share by 2025 end.

On the basis of injury type, the global spinal cord trauma treatment market is segmented into complete spinal cord injuries and partial spinal cord injuries. Partial spinal cord trauma treatment segment is expected to show better growth than the completed spinal cord treatment segment due to higher growth in the incidence rate of partial spinal cord trauma than the complete spinal cord trauma. With US$ 1,870.3 Mn market value in 2025, this segment is likely to expand at CAGR 3.8% throughout the projected period.

On the basis of treatment type, the global spinal cord trauma treatment market is segmented into corticosteroid, surgery, and spinal traction segments. Surgery segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Surgery segment is the most attractive segment, with attractiveness index of 2.6 over the forecast period.

This market is segmented into five regions such as North America, Latin America, Europe, APAC and MEA. Asia-Pacific account for the largest market share in the global spinal cord trauma treatment market. Large patient population due to the high rate of road accidents and crime is making the Asia Pacific region most attractive market for spinal cord trauma treatment. On the other hand, MEA and Latin America is expected to be the least attractive market for spinal cord trauma treatment, with attractiveness index of 0.3 and 0.5 respectively over the forecast period.

Acorda Therapeutics, Inc., Asterias Biotherapeutics, ReNetX Bio, BioArctic AB, BioTime, Inc., InVivo Therapeutics, Kringle Pharma, Inc., Novartis AG, Pfizer Inc., Pharmicell Co. Ltd., Vertex Pharmaceuticals Inc., and Bioaxone Biosciences, Inc. are some of the key players in the global spinal cord trauma treatment market.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Swine and Avian Influenza Drug Development Pipeline Review, 2017

This report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and discontinued projects.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. There are a total of 63 products in development for this indication, by 47 companies and six academic institutions.

H1N1 Infection also called as swine flu is a new kind of flu in humans. Its caused by the contagious H1N1 influenza virus. There are a total of 99 products in development for this indication, by 67 companies and 14 academic institutions.

In both types of influenza, the most common molecular target being studied is hemagglutinin, by a considerable margin. However, a number of both human and viral proteins are also under active development.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Swine and Avian Influenza Report Coverage 8
2.2 Influenza A Virus, H5N1 Subtype Infections — Overview 8
2.3 Influenza A Virus, H1N1 Subtype Infections — Overview 8
3 Therapeutics Development 9
3.1 Influenza A Virus, H5N1 Subtype Infections 9
3.2 Influenza A Virus, H1N1 Subtype Infections 18
4 Therapeutics Assessment 30
4.1 Influenza A Virus, H5N1 Subtype Infections 30
4.2 Influenza A Virus, H1N1 Subtype Infections 36
5 Companies Involved in Therapeutics Development 43
5.1 Influenza A Virus, H5N1 Subtype Infections 43
5.2 Influenza A Virus, H1N1 Subtype Infections 58
6 Dormant Projects 81
6.1 Influenza A Virus, H5N1 Subtype Infections 81
6.2 Influenza A Virus, H1N1 Subtype Infections 86
7 Discontinued Products 90
7.1 Influenza A Virus, H5N1 Subtype Infections 90
7.2 Influenza A Virus, H1N1 Subtype Infections 90
8 Product Development Milestones 91
8.1 Influenza A Virus, H5N1 Subtype Infections 91
8.2 Influenza A Virus, H1N1 Subtype Infections 103
9 Appendix 118
9.1 Methodology 118
9.2 Coverage 118
9.3 Secondary Research 118
9.4 Primary Research 118
9.5 Expert Panel Validation 118
9.6 Contact Us 119
9.7 Disclaimer 119

CONTACT US:
New York City Zone 01,
NY, United States.
International: (+1) 646 781 7170
UK (Toll free): +44 800 088 5734
Email: help@24marketreports.com

Riya Sharma is a Digital Marketer by professional and she has a great experience in blogging, content writing and SEO.

Spirulina Market – Global Indutry Insights and Forecast till 2022

worldwidemarketreports

Spirulina is a microscopic spiral shaped blue-green vegetable algae which grows in mineral-rich freshwater and saltwater sources. It provides an abundance of protein, vitamins, minerals, trace minerals, essential fatty acids, phytonutrients, and antioxidants.
Scope of the Report:
This report focuses on the Spirulina in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, Southeast Asia, India and Australia. This report categorizes the market based on manufacturers, countries/Regions, type and application.


Market Segment by Manufacturers, this report covers
DIC
Cyanotech
Parry Nutraceuticals
Hydrolina Biotech
King Dnarmsa
CBN
Green-A
Spirin
Chenghai Bao ER
Shenliu
SBD
Lanbao
Tianjian
Wuli Lvqi
Gangfa

Market Segment by Countries, covering
China
Japan
Korea
Taiwan
Southeast Asia
India
Australia

Market Segment by Type, covers
Spirulina Powder
Spirulina Tablet
Spirulina Extracts

Market Segment by Applications, can be divided into
Health Products
Feed
Others

Table of Contents
1 Market Overview
1.1 Spirulina Introduction
1.2 Market Analysis by Type
1.2.1 Spirulina Powder
1.2.2 Spirulina Tablet
1.2.3 Spirulina Extracts
1.3 Market Analysis by Applications
1.3.1 Health Products
1.3.2 Feed

2.2.3 Cyanotech Spirulina Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.4 Business Overview
2.2.5 Cyanotech News
2.3 Parry Nutraceuticals
2.3.1 Profile

About WMR :

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

#3200

Seattle, WA 98154,

U.S

Tel: +1 415 871 0703

Email: sales@worldwidemarketreports.com

Pranali is a BCA in computer science by education and a technology enthusiast by passion. She has a stint of experience in Blogging and SEO and loves to write.

Blood Cancer Diagnostics Market: Top 9 Takeaways

Blood Cancer Diagnostics

Fact.MR, in its recent research, offers market forecast and analysis on the blood cancer diagnostics market for the period, 2017-2022. According to the research, the global blood cancer diagnostics market is projected to grow at 6.4% CAGR through 2022. The key takeaways from Fact.MR’s research report include,

  • By test type, the CBC segment, which is currently valued at nearly US$ 77 million, is projected to grow at nearly 5% CAGR. In the North America blood cancer diagnostics market, these tests will continue to account for a significant share of overall revenues.
  • Owing to highly accurate diagnosis, blood testing will also continue to be a widely used test globally. Fact.MR projects this segment to rake in significant revenues by 2022.
  • On back of recent reports about the accuracy and benefits of using liquid biopsy, this segment is gaining traction globally. Research carried out at Massachusetts General Hospital Cancer Center and Harvard Medical School has shown that liquid biopsy can help patients with advanced cholangiocarcinoma. Fact.MR projects this segment to grow at a high CAGR through 2022.
  • The bone marrow test type is also being widely used by end-users owing to its efficacy in diagnosis and management. According to Fact.MR’s analysis, the bone marrow test type is anticipated to rake in significant revenues during the forecast period. Revenues from this segment are anticipated to grow at a healthy CAGR through 2022.
  • Hospital associated labs account for a significant revenue share of the overall demand for blood cancer diagnostics. According to Fact.MR’s analysis, this end-use segment is projected to grow at over 6% CAGR through 2022.
  • Independent diagnostic laboratories are also a major end-user of blood cancer diagnostics. Fact.MR estimates revenues from this segment to grow at over 6% CAGR through 2022. Demand is also anticipated to be strong from the cancer research institutes segment.
  • The blood cancer diagnostics market in the U.S. will continue to account for a significant share of the global revenues. The U.S. will also remain significant owing to R&D and new developments in diagnostics. Fact.MR projects the U.S. blood cancer diagnostics market to account for leading revenue share of the global market.
  • In Europe, Germany and U.K. will account for significant revenue share of the global revenues. Advancements in R&D, combined with increasing prevalence of the disease will hamper growth of the market.
  • Leading companies in the market are focusing on investing in R&D to come up with innovative and accurate diagnostics solutions. Mergers and acquisitions, and collaborations will continue to remain a trend in this market.

The report has also profiled key players in the global market for blood cancer diagnostics, which include companies such as Abbott Laboratories, Thermo Fisher Scientific Inc., Roche Holding A.G., Laboratory Corporation of America Holdings, Luminex Corporation, NanoString Technologies Inc, Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Quest Diagnostics Incorporated, Siemens AG, Qiagen N.V., Biotheranostics, Inc, Agilent Technologies, Almac Group Limited, and GeneNews Limited.

Check Discount- https://www.factmr.com/connectus/sample?flag=D&rep_id=47

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/

Yogesh is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO.

Telemedicine Carts & Systems Market – Global Indutry Insights and Forecast till 2022

worldwidemarketreports

Telemedicine Carts & Systems Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).

The report firstly introduced the Telemedicine Carts & Systems basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with:
1.) basic information;
2.) the Asia Telemedicine Carts & Systems Market;
3.) the North American Telemedicine Carts & Systems Market;
4.) the European Telemedicine Carts & Systems Market;
5.) market entry and investment feasibility;
6.) the report conclusion.

Table of Contents

Part I Telemedicine Carts & Systems Industry Overview

Chapter One Telemedicine Carts & Systems Industry Overview
1.1 Telemedicine Carts & Systems Definition
1.2 Telemedicine Carts & Systems Classification Analysis
1.2.1 Telemedicine Carts & Systems Main Classification Analysis
1.2.2 Telemedicine Carts & Systems Main Classification Share Analysis
1.3 Telemedicine Carts & Systems Application Analysis
1.3.1 Telemedicine Carts & Systems Main Application Analysis
1.3.2 Telemedicine Carts & Systems Main Application Share Analysis
1.4 Telemedicine Carts & Systems Industry Chain Structure Analysis
1.5 Telemedicine Carts & Systems Industry Development Overview
1.5.1 Telemedicine Carts & Systems Product History Development Overview
1.5.1 Telemedicine Carts & Systems Product Market Development Overview
1.6 Telemedicine Carts & Systems Global Market Comparison Analysis
1.6.1 Telemedicine Carts & Systems Global Import Market Analysis
1.6.2 Telemedicine Carts & Systems Global Export Market Analysis
1.6.3 Telemedicine Carts & Systems Global Main Region Market Analysis
1.6.4 Telemedicine Carts & Systems Global Market Comparison Analysis
1.6.5 Telemedicine Carts & Systems Global Market Development Trend Analysis

About WMR :

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

#3200

Seattle, WA 98154,

U.S

Tel: +1 415 871 0703

Email: sales@worldwidemarketreports.com

Pranali is a BCA in computer science by education and a technology enthusiast by passion. She has a stint of experience in Blogging and SEO and loves to write.

5 Key Forecasts on Growth of Bone Growth Stimulator Market through 2022

Bone Growth Stimulator

As patients of spinal cord fractures continue to struggle with long duration consumed for complete recovery, surgeons and doctors continue to promote the use of bone growth stimulators. The Fact.MR forecast report on global bone growth stimulator market anticipates that global sales of these devices will bring in more than US$ 1.4 Bn by the end of 2017. Spinal fracture patients opting for bone growth stimulators is expected to rise due to increasing advancements in lowering patient discomfort. By the end of 2022, sales of bone growth stimulators in the global market is pegged to bring in US$ 1.91 Bn, exhibiting a steady growth at 5.3% CAGR.

Key Forecast Highlights

  1. According to the report, bone growth stimulation devices will account for nearly 56% share on global bone growth stimulator revenues in 2017. Platelet-rich plasmas, on the other hand, will be observed as promising product segment, revenues from which are expected to showcase robust growth at 6.2% CAGR. By the end of 2022, a little over US$ 450 Mn worth of platelet-rich plasmas will be sold in the global market for bone growth stimulators.
  2. In the view of poor road infrastructure and inferior healthcare facilities existing in the Asia-Pacific excluding Japan (APEJ) region, the demand for bone growth stimulators is expected to gain grounds. These factors are boosting the incidence of spinal fractures in this region, compelling doctors towards adoption of bone growth simulation therapy. Moreover, manufacturers of bone growth stimulators are expected to benefit from low wage costs and high resource availability by setting up their manufacturing units across APEJ region. By the end of 2022, over US$ 225 Mn worth of bone growth stimulators will be sold across the APEJ market.
  3. North America is expected to remain the largest market for bone growth stimulator. The report predicts that high healthcare spending implemented in Canada and the US will urge manufacturers towards developing advanced bone growth stimulators. Meanwhile, revenues amassed from sales of bone growth stimulators in Europe will contribute US$ 600 Mn in revenues by the end of 2022. Towards the end of forecast period, North America’s bone growth stimulator market is likely to soar at a CAGR of 6.2%.
  4. Application of bone growth stimulators in delayed union & non-union bone fracture treatments is expected to gain traction, reflecting a revenue growth at 5.7% CAGR. Spinal fusion surgeries will account for nearly 25% of the global bone growth stimulator sales in 2017, while their application in oral and maxillofacial surgeries will procure around US$ 250 Mn in global revenues.
  5. Hospitals and clinics are expected to remain largest end-users of bone growth stimulator throughout the forecast period. With more than 43% share, over US$ 800 Mn worth of bone growth stimulators will be sold in hospitals & clinics across the globe by 2022-end. Home care end-use of bone growth stimulator, on the other hand, is expected to create an incremental opportunity of more than US$ 100 Mn by 2022 over 2017.

The report has also profiled leading players in the global bone growth stimulator market, which include companies such as Orthofix International N.V., Medtronic plc, Zimmer Biomet Holdings, Inc., Bioventus Inc., Stryker Corporation, Johnson & Johnson, Arthrex, Inc., DJO Global Inc., Elizur Corporation, and Ossatec Benelux B.V.

Check Discount- https://www.factmr.com/connectus/sample?flag=D&rep_id=54

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/

Yogesh is a Digital Marketer by professional and he has a great experience in blogging, content writing and SEO.